Recent Updates
Recently added Catalysts
TMDX Positive Sentiment Score: 75/100

TransMedics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference TransMedics Group, Inc. ( TransMedics ) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with...

Key Takeaway: TransMedics Group, Inc. announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 13, 2025. The presentation will showcase the company's advancements in organ transplant therapy, particularly in addressing end-stage lung, heart, and liver failure. A live webcast will be available for investors, emphasizing the company's commitment to increasing organ viability and utilization. TransMedics is recognized as a leader in the portable extracorporeal warm perfusion technology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a key industry conference enhances visibility.
  • Innovative technologies for organ transplant therapy are highlighted.
  • Focus on meeting the unmet needs in organ donation and transplantation.

Full Press Release Details

ANDOVER, Mass. , Dec. 23, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that members of the management team will present at the upcoming 43 rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025 , at 2:15 p.m. Pacific Standard Time / 5:15 p.m. Eastern Standard Time .
Event: 43 rd Annual J.P. Morgan Healthcare Conference Date: Monday, January 13, 2025 Time: 2:15 p.m. PST
A live and archived webcast of the presentation will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com/ . The Company's standard investor presentation is also available through this link.
About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure.
Investor Contact: Brian Johnston Laine Morgan 332-895-3222 [email protected]
SOURCE TransMedics Group, Inc.

21 %

Frequently Asked Questions

When is TransMedics presenting at the J.P. Morgan Conference?

TransMedics will present on January 13, 2025, at 2:15 p.m. PST.

Where can I watch the TransMedics presentation?

You can watch the presentation on the TransMedics investors' webpage.

What is TransMedics' primary focus?

TransMedics focuses on improving organ transplant therapies for end-stage organ failure.

What technologies does TransMedics develop?

TransMedics develops technologies to preserve and assess donor organs for transplantation.

Where is TransMedics headquartered?

TransMedics is headquartered in Andover, Massachusetts.

Last updated: Dec 23, 2024